Is it acceptable to do IFRT rather than whole posterior fossa boost for high risk medulloblastoma?  

 If so in what circumstances and what margin is acceptable? ACNS 0331 recently showed no difference in outcomes when comparing IFRTboost vs PF boost for standard risk but high risk medulloblastoma trials still do PF boost.



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice